Prokidney

Inregen

Tengion, Inc.

The University of North Carolina at Chapel Hill

Vesta Therapeutics Inc.

Louisiana State University and Agricultural & Mechanical College

Artecel, Inc

Regenmedtx, LLC

Regenmed, Inc.

Exoceuticals, Inc.

Exotropin, LLC

Incara Cell Technologies, Inc.

John W Ludlow

Andrew T Bruce

Joydeep Basu

Kelly Guthrie

Manuel J Jayo

Deepak Jain

Richard Payne

Namrata D Sangha

Timothy A Bertram

Oluwatoyin A Knight

Russell W Kelley

Roger M Ilagan

Darell McCoy

Christopher W Genheimer

Sharon C Presnell

Shay M Wallace

Eric S Werdin

Sumana Choudhury

Craig R Halberstadt

Neil F Robins

Dominic Justewicz

Teresa Burnette

Bryan R Cox

Benjamin Watts

Thomas Spencer

Elias A Rivera

Lola M Reid

Mark E Furth

H Scott Rapoport

Kelly I Guthrie

Nicholas Moss

Sarah F Quinlan

Jeffery M Gimble

Teresa B Burnette

Jacob E Shokes

Sarah A Boyd

Dominic M Justewicz

Wendy Sharp

Andrew Bruce

Peter Pieraccini

Benjamin Buehrer

Darrell Mccoy

Darell Mccoy

Nicholas G Moss

Neil F Robbins

The present invention concerns enriched heterogeneous mammalian renal cell populations characterized by biomarkers, and methods of making and using the same.

Renal cell populations and uses thereof

The present invention concerns bioactive renal cell populations, renal cell constructs, and methods of making and using the same.

Bioactive renal cells

The present invention concerns bioactive renal cells populations, renal cell constructs, and methods of making and using the same.

The present invention relates to the regeneration, reconstruction, repair, augmentation or replacement of organs or tissue structures using scaffolds and autologous cells that are not derived from such organs or tissues.

Cell scaffold constructs

The present invention provides a method to derive hepatic stem cells from stem cells derived from non-liver tissue. In one embodiment of the invention, hepatic stem cells are derived from adipose stem cells. The invention also provides a method of enhancing hepatic cytokine production (e.g., HGF) from ASCs, which may be useful in the regeneration of liver tissue when transplanted in vivo. Tissue culture conditions, including media conditions, are provided.

Adipose derived adult stem cells in hepatic regeneration

Biocompatible synthetic or natural scaffolds are provided for the reconstruction, repair, augmentation or replacement of organs or tissue structures in a patient in need of such treatment. The scaffolds are shaped to conform to at least a part of the organ or tissue structure and may be seeded with one or more cell populations. Inserts, receptacles and ports are also provided for the attachment of tubular vessels to the neo-organ scaffolds. The seeded scaffolds are implanted into the patient at the site in need of treatment to form an organized organ or tissue structure. The scaffolds may be used to form organs or tissues, such as bladders, urethras, valves, and blood vessels.

Scaffolds for organ reconstruction and augmentation

Hepatic progenitors comprise two populations of human hepatic stem cells, primitive and proximal hepatic stem cells, and two populations of committed progenitors, one for biliary cells and one for hepatocytes. Human primitive hepatic stem cells are a very small fraction of the liver cell population and give rise to proximal hepatic stem cells constituting a much larger fraction of the liver. Human proximal hepatic stem cells give rise to biliary and hepatocyte committed progenitors. Primitive and proximal stem cells are the primary stem cells for the human liver. Human primitive hepatic stem cells may be isolated by immunoselection from human livers or culturing human liver cells under conditions which select for a human primitive hepatic stem cell. Proximal hepatic stem cells may be isolated by immunoselection, or by culturing human liver cells under conditions which include a developmental factor. Proximal hepatic stem cells may also be isolated by culturing colonies comprising a primitive hepatic stem cell under conditions which include a developmental factor. Resulting compositions may be used for treating liver disorders and for producing bioartificial organs.

Primitive and proximal hepatic stem cells

Cell-scaffold constructs

Growing community of inventors

Carrboro, NC, United States of America

John W Ludlow